<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6374">
  <stage>Registered</stage>
  <submitdate>19/01/2017</submitdate>
  <approvaldate>19/01/2017</approvaldate>
  <nctid>NCT03089645</nctid>
  <trial_identification>
    <studytitle>MEDI5083 Alone and in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors</studytitle>
    <scientifictitle>A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone and in Combination With Durvalumab in Selected Advanced Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>D6840C00001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Selected Advanced Solid Tumors</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - MEDI5083 monotherapy
Other interventions - MEID5083 with durvalumab

Experimental: Part 1 - MEDI5083 monotherapy

Experimental: Part 2 - MEDI5083 with durvalumab


Other interventions: MEDI5083 monotherapy
Dose-escalation MEDI5083 monotherapy

Other interventions: MEID5083 with durvalumab
MEDI5083 dose-escalation with durvalumab therapy

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with Adverse Events (AEs) as a measure of safety - Safety Endpoint</outcome>
      <timepoint>From the time of consent through 120 days after last treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with Serious Adverse Events (SAEs) as a measure of safety - Safety Endpoint</outcome>
      <timepoint>From the time of consent through 120 days after last treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of participants with Dose Limiting Toxicities (DLTs) as a measure of safety - Safety Endpoint</outcome>
      <timepoint>From the time of first dose through 28 days thereafter</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The Maximum Tolerated Dose (MTD) or Highest Protocol-Defined Dose - Safety Endpoint</outcome>
      <timepoint>From the time of first dose through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Discontinuation Rate - Safety Endpoint</outcome>
      <timepoint>From the time of first dose through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum MEDI5083 concentration levels - Pharmacokinetics (PK)</outcome>
      <timepoint>From the time of first dose through 57 days after first treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction in peripheral blood CD19+ B cells - Pharmacodynamics (PD)</outcome>
      <timepoint>From the time of first dose through 57 days after first treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of anti-drug antibody (ADA) responses to MEDI5083 - Immunogenicity</outcome>
      <timepoint>From the time of first dose through 2 years after last treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response Rate (ORR) - Clinical Activity Endpoint</outcome>
      <timepoint>From the time of consent through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival (PFS) at 6 months (PFS-6) - Clinical Activity Endpoint</outcome>
      <timepoint>From the time of first dose until 6 months after the last subject is dosed</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) - Clinical Activity Endpoint</outcome>
      <timepoint>From the time of consent through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Control Rate (DCR) - Clinical Activity Endpoint</outcome>
      <timepoint>From the time of consent through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response (DoR) - Clinical Activity Endpoint</outcome>
      <timepoint>From the time of consent through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum Durvalumab concentration levels - Pharmacokinetics (PK)</outcome>
      <timepoint>From the time of first dose through 29 days after first treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of anti-drug antibody (ADA) responses to Durvalumab - Immunogenicity</outcome>
      <timepoint>From the time of first dose through 2 years after last treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age = 18 years at the time of screening or age of consent according to local law

          2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          3. Histologically or cytologically confirmed metastatic or recurrent tumor types

          4. Subjects who have received prior immunotherapy may be eligible

          5. Subjects must have at least one measurable lesion

          6. Consent to provide archival tumor tissue and pre/on-treatment biopsies

          7. Adequate organ and marrow function

          8. Consent to use one highly effective method of contraception</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Receipt of any systemic anticancer therapy within 28 days prior to the first dose of
             MEDI5083

          2. Concurrent enrollment in another clinical study

          3. Active/prior autoimmune of inflammatory disorders

          4. History of immunodeficiency, solid organ transplant, or tuberculosis

          5. Known allergy/hypersensitivity to drug or components

          6. Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or
             cord compression

          7. Current or prior use of immunosuppressive medication within 14 days prior to the first
             dose of MEDI5083</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Other</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>21/03/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>204</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>15/08/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Site - Melbourne</hospital>
    <postcode>3000 - Melbourne</postcode>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>MedImmune LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and
      antitumor activity in adult subjects with selected advanced solid tumor malignancies.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03089645</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MedImmune LLC</name>
      <address>Sponsor GmbH</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>AstraZeneca Clinical Study Information Center</name>
      <address />
      <phone>1-877-240-9479</phone>
      <fax />
      <email>information.center@astrazeneca.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>